Vectibix Purple Book BLA 125147

BLA number
125147
Proprietary names
Vectibix
Proper names
panitumumab
Applicant
Amgen Inc.
Center
CDER
First observed release
2020-05-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Vectibixpanitumumab351(a)100MG/5ML (20MG/ML)InjectionIntravenousSingle-Dose VialRxLicensed2006-09-27
002Vectibixpanitumumab351(a)400MG/20ML (20MG/ML)InjectionIntravenousSingle-Dose VialRxLicensed2006-09-27
003Vectibixpanitumumab351(a)200MG/10ML (20MG/ML)InjectionIntravenousSingle-Dose VialDiscLicensed2006-09-27

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2020-10-01U001Vectibix351(a)RxAmgen, Inc.
2020-10-01U002Vectibix351(a)RxAmgen, Inc.
2020-10-01U003Vectibix351(a)DiscAmgen, Inc.
2020-05-01R001Vectibix351(a)RxAmgen Inc.
2020-05-01R002Vectibix351(a)RxAmgen Inc.
2020-05-01R003Vectibix351(a)DiscAmgen Inc.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2020-05-01001Vectibix351(a)RxLicensed2006-09-27
2020-05-01002Vectibix351(a)RxLicensed2006-09-27
2020-05-01003Vectibix351(a)DiscLicensed2006-09-27